Home›Companies›Biotech & Pharma›EvolveImmune Therapeutics

EvolveImmune Therapeutics Holding Company, LLC

Develops immune-based cancer treatments for patients with solid tumors and blood cancers.

Updated Nov 19, 2026·Latest SEC filing Nov 1, 2024·Suggest an edit

About EvolveImmune Therapeutics

EvolveImmune Therapeutics is a private company based in Branford, Connecticut, incorporated in 2019 in Delaware. It has reported $85,776,146 raised in four offerings on Form D since January 2020. Its chief executive is Stephen Bloch.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Oct 22, 2024Nov 1, 2024$20,000,003fully sold1$20.0MEquityRule 506(b)Form D ↗
Nov 15, 2023Nov 16, 2023$37,398,371of $57.3M target9$4.1MEquityRule 506(b)Form D ↗
Jan 18, 2023Jan 19, 2023$10,827,780of $26.0M target8$1.3MDebt, Options, Convertible Promissory NotesRule 506(b)Form D ↗
Jan 8, 2020Jan 17, 2020$17,549,992of $35.0M target8$2.1MEquityRule 506(b)Form D ↗
Total, four offerings$85,776,146

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on EvolveImmune Therapeutics's Form D filed Nov 1, 2024.

Donmienne Leung
Donmienne Leung
Director
First appears on the Form D that EvolveImmune Therapeutics filed on November 1, 2024; on 1 of its 4 filings.
Donmienne Leung appears on 2 Form D filings at 2 companies:
  • EvolveImmune Therapeutics, director: Nov 1, 2024
  • EndLyz, director, AbbVie ventures: May 7, 2026
IT
Ian Taylor
Director
First appears on the Form D that EvolveImmune Therapeutics filed on January 19, 2023; on 3 of its 4 filings.
DY
Derek Yoon
Director
First appears on the Form D that EvolveImmune Therapeutics filed on January 19, 2023; on 3 of its 4 filings.
Stephen Bloch
Stephen Bloch
Co-founder and Chief Executive Officer, director
On every Form D that EvolveImmune Therapeutics has filed: 4 filings, from Jan 17, 2020 to Nov 1, 2024.
Stephen Bloch appears on 23 Form D filings at 8 companies. Show all
  • Marinus Pharmaceuticals, chairman of the board of directors: Apr 22, 2009
  • Liquidia Technologies, chairman: Jul 15, 2009 · Jan 21, 2010 (amended) · May 25, 2010 (amended) · Mar 3, 2011 · Jul 2, 2012 (amended) · Feb 20, 2018 · Jan 7, 2020
  • Envisia Therapeutics, director: Nov 22, 2013
  • LQ3 Pharmaceuticals, director: Jul 23, 2014 · Dec 17, 2014 (amended)
  • Envisia Therapeutics, director: Oct 19, 2015 · Mar 17, 2016
  • EvolveImmune Therapeutics, co-founder and chief executive officer, director: Jan 17, 2020 · Jan 19, 2023 · Nov 16, 2023 · Nov 1, 2024
  • Liquidia, director: Apr 16, 2021
  • Allyx Therapeutics, CEO & co-founder, director: Jun 2, 2021 · Feb 10, 2023 · Mar 3, 2026 · May 11, 2026 · Oct 21, 2026 (amended)
JM
Jasmina Marjanovic
Director
First appears on the Form D that EvolveImmune Therapeutics filed on November 1, 2024; on 1 of its 4 filings.
DP
Denis Patrick
Director
On every Form D that EvolveImmune Therapeutics has filed: 4 filings, from Jan 17, 2020 to Nov 1, 2024.

Earlier filings also listed

  • Alessandra Di Bacco · director
    Last listed on the Form D that EvolveImmune Therapeutics filed on November 16, 2023; on 3 of its 4 filings.
  • Hugo Beekman · director
    Last listed on the Form D that EvolveImmune Therapeutics filed on January 17, 2020; on 1 of its 4 filings.

Sources

  1. SECEvolveImmune Therapeutics Holding Company, LLC filing history
  2. CompanyEvolveImmune Therapeutics team
  3. CompanyEVOLVE104 clinical trial announcement